The purpose of this research study is to be
studying the safety of this drug, including any side effects related to its use
and how well the symptoms are tolerated, while also learning if the study drug MDGN-002
might be useful in treating Crohn’s disease and its symptoms. . MDGN-002 is a
research therapy that has been tested before in adults using a single dose.
MDGN-002 is not yet approved by the United States Food and Drug Administration
(FDA).
How long will you be in this study?
If you agree to take part, the treatment
period will last for 84 days and will involve upto 12 study visits. Study
visits will last between 1 and 8 hours. There will be upto 2 study-related telephone
calls.
The total duration of being in the
study is about 26 weeks.
How understandable was the trial content above?
Hard to understand
Easy to understand
